AIMS/HYPOTHESIS: Recent studies suggest that loss of heparan sulphate in the glomerular basement membrane (GBM) of the kidney with diabetic nephropathy is due to the increased production of heparanase, a heparan sulphate-degrading endoglycosidase. Our present study addresses whether heparan sulphate with different modifications is differentially reduced in the GBM and whether heparanase selectively cleaves heparan sulphate with different domain specificities. METHODS: The heparan sulphate content of renal biopsies (14 diabetic nephropathy, five normal) were analysed by immunofluorescence staining with four anti-heparan sulphate antibodies: JM403, a monoclonal antibody (mAb) recognising N-unsubstituted glucosamine residues; two phage display-derived single chain antibodies HS4C3 and EW3D10, defining sulphated heparan sulphate domains; and anti-K5 antibody, an mAb recognising unmodified heparan sulphate domains. RESULTS: We found that modified heparan sulphate domains (JM403, HS4C3 and EW3D10), but not unmodified domains (anti-K5) and agrin core protein were reduced in the GBM of kidneys from patients with diabetic nephropathy, compared with controls. Glomerular heparanase levels were increased in diabetic nephropathy kidneys and inversely correlated with the amounts of modified heparan sulphate domains. Increased heparanase production and loss of JM403 staining in the GBM correlated with the severity of proteinuria. Loss of modified heparan sulphate in the GBM as a result of degradation by heparanase was confirmed by heparan sulphate staining of heparanase-treated normal kidney biopsy specimens. CONCLUSIONS/ INTERPRETATION: Our data suggest that loss of modified heparan sulphate in the GBM is mediated by an increased heparanase presence and may play a role in the pathogenesis of diabetes-induced proteinuria.
AIMS/HYPOTHESIS: Recent studies suggest that loss of heparan sulphate in the glomerular basement membrane (GBM) of the kidney with diabetic nephropathy is due to the increased production of heparanase, a heparan sulphate-degrading endoglycosidase. Our present study addresses whether heparan sulphate with different modifications is differentially reduced in the GBM and whether heparanase selectively cleaves heparan sulphate with different domain specificities. METHODS: The heparan sulphate content of renal biopsies (14 diabetic nephropathy, five normal) were analysed by immunofluorescence staining with four anti-heparan sulphate antibodies: JM403, a monoclonal antibody (mAb) recognising N-unsubstituted glucosamine residues; two phage display-derived single chain antibodies HS4C3 and EW3D10, defining sulphated heparan sulphate domains; and anti-K5 antibody, an mAb recognising unmodified heparan sulphate domains. RESULTS: We found that modified heparan sulphate domains (JM403, HS4C3 and EW3D10), but not unmodified domains (anti-K5) and agrin core protein were reduced in the GBM of kidneys from patients with diabetic nephropathy, compared with controls. Glomerular heparanase levels were increased in diabetic nephropathy kidneys and inversely correlated with the amounts of modified heparan sulphate domains. Increased heparanase production and loss of JM403 staining in the GBM correlated with the severity of proteinuria. Loss of modified heparan sulphate in the GBM as a result of degradation by heparanase was confirmed by heparan sulphate staining of heparanase-treated normal kidney biopsy specimens. CONCLUSIONS/ INTERPRETATION: Our data suggest that loss of modified heparan sulphate in the GBM is mediated by an increased heparanase presence and may play a role in the pathogenesis of diabetes-induced proteinuria.
Authors: Giovanni Gambaro; Ida Kinalska; Adrian Oksa; Peter Pont'uch; Miluse Hertlová; Jindrich Olsovsky; Jacek Manitius; Domenico Fedele; Stanislaw Czekalski; Jindriska Perusicová; Jan Skrha; Jan Taton; Wladyslaw Grzeszczak; Gaetano Crepaldi Journal: J Am Soc Nephrol Date: 2002-06 Impact factor: 10.121
Authors: B Myrup; P M Hansen; T Jensen; A Kofoed-Enevoldsen; B Feldt-Rasmussen; J Gram; C Kluft; J Jespersen; T Deckert Journal: Lancet Date: 1995-02-18 Impact factor: 79.321
Authors: Joost F M Lensen; Angelique L W M M Rops; Tessa J M Wijnhoven; Theo Hafmans; Wouter F J Feitz; Egbert Oosterwijk; Bernhard Banas; René J M Bindels; Lambert P W J van den Heuvel; Johan van der Vlag; Jo H M Berden; Toin H van Kuppevelt Journal: J Am Soc Nephrol Date: 2005-03-23 Impact factor: 10.121
Authors: Vicki Levidiotis; Craig Freeman; Malcolm Punler; Paul Martinello; Brian Creese; Vito Ferro; Johan van der Vlag; Jo H M Berden; Christopher R Parish; David A Power Journal: J Am Soc Nephrol Date: 2004-11 Impact factor: 10.121
Authors: Els M A van de Westerlo; Toon F C M Smetsers; Michel A B A Dennissen; Robert J Linhardt; Jacques H Veerkamp; Goos N P van Muijen; Toin H van Kuppevelt Journal: Blood Date: 2002-04-01 Impact factor: 22.113
Authors: Sunil Rangarajan; Jillian R Richter; Robert P Richter; Shyam K Bandari; Kaushlendra Tripathi; Israel Vlodavsky; Ralph D Sanderson Journal: J Histochem Cytochem Date: 2020-07-06 Impact factor: 2.479
Authors: G Rao; H G Ding; W Huang; D Le; J B Maxhimer; A Oosterhof; T van Kuppevelt; H Lum; E J Lewis; V Reddy; R A Prinz; X Xu Journal: Diabetologia Date: 2011-03-20 Impact factor: 10.122